Agony in the Antipodes: The Generic Drug Provisions of the Australia-U.S. Free Trade Agreement

Author granted license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

Document Type

Article

Publication Date

2005

ISSN

1741-1343

Publisher

Sage Publications

Language

en-US

Abstract

The Australia-U.S. Free Trade Agreement (AUSFTA), which entered into force on January 1, 2005, contains many remarkable provisions of interest to generic drug companies. The AUSFTA selectively exports U.S. generic drug laws of great import to generic drug manufacturers, and is uniquely intrusive into domestic pharmaceutical and political spheres. The AUSFTA is important both in its own right, and as a model for future U.S. free trade agreement negotiations.

Beyond the generic drug industry, the provisions are of interest to consumers who pay higher prices when generic drug entry is delayed, and stands as an example of the lack of transparency and accountability in the negotiation of free trade agreements.

This document is currently not available here.

Find on SSRN

Please note the file available on SSRN may not be the final published version of this work.

Link to Publisher Site Link to Publisher Site (BU Community Subscription)

Share

COinS